Benzodiazepine Analogues. Part 20.‡ Mass Spectrometric Analysis of Benzoxathiepine Derivatives†

Aifheli C. Gelebe§ and Perry T. Kaye*

Department of Chemistry, Rhodes University, P.O. Box 94, Grahamstown, 6140, South Africa

Fragmentation patterns in the electron-impact (EI) mass spectra of benzoxathiepine derivatives are elucidated using a combination of high-resolution and comparative low-resolution mass spectrometric analysis.

While the clinical use of benzodiazepines as anxiolytics is well established, a number of sulfur-containing analogues also exhibit useful medicinal properties. These analogues include the cardiac drug, diltiazem,² and the antimicrobial, 3H-1,5-benzoxathiepine-2,4-dione.³ As part of an ongoing investigation of benzodiazepine analogues, we have reported the synthesis of various benzoxathiepine derivatives⁴ and, here, we discuss the results of a mass spectrometric study of the latter compounds.

A combination of high-resolution, comparative lowresolution and metastable peak data was used to investigate the fragmentation of three series of benzoxathiepines, *viz.*, the 4-phenyl-1,5-benzoxathiepin-2-ones 1-5, the 3-phenyl-4,1-benzoxathiepin-5-ones 6-8 and the 3-phenyl-4,1-benzoxathiepines 9-12. Selected MS data for these compounds are summarised in Table 1, while the proposed fragmentation pathways are outlined in Schemes 1-3.



Scheme 1 Mass-spectral fragmentation pathways for 4-phenyl-1,5-benzoxathiepin-2-one $\mathbf{1}(R = H)$. Accurate masses (m/z) are followed, in parentheses, by calculated formula masses; an asterisk indicates a pathway supported by the metastable peak given in parentheses.

4-Phenyl-1,5-benzoxathiepin-2-ones 1-5.—Fragmentation in these systems appears to follow three major pathways. In Path I (illustrated for the parent system 1 in Scheme 1), cleavage of the heterocycle, presumably via radical cations of type **b**, isomeric in each case with the molecular ion **a**, affords the conjugated acylium cations **c**. Even-electron species of this type (**c**) account for the base peak for each of the compounds examined; decarbonylation then leads to the C-ring fragments **d**. Metastable peaks in the mass spectrum of the parent system 1 provide confirmation of the fragmentations 1a/b $(m/z \ 256) \rightarrow 1c(m/z \ 131) \rightarrow 1d(m/z \ 103)$.



Scheme 2 Mass-spectral fragmentation pathways for 3-phenyl-4,1-benzoxathiepin-5-one **6** (R = H). Other details as for Scheme 1.

Two distinct, intra-annular rearrangements (Fig. 1) account for the fragmentations $a \to e~(\mbox{Path II})$ and $\mathbf{a} \rightarrow \mathbf{h}$ (Path III). In the former, migration of O(1) to C(4) results in extrusion of ketene affording the ring-contracted benzoxathiolane species e; in the latter, migration of the sulfur to C(2) results in the loss of benzoxathiolan-2-one and detection of a styryl radical cation h. Loss of H[.] or a phenyl radical from the benzoxathiolane radical cation e then accounts for the resonance-stabilised fragments f and g. These intra-annular rearrangements parallel those observed in our earlier study of 1,5-benzodioxepin-2-one analogues⁵ and, in fact, both series of compounds exhibit rather similar fragmentation patterns. Inspection of the mass contribution of the 4-substituents (R, Table 1) confirms that the ions of type g are A-ring fragments, ion-types c, d and h are C-ring fragments and ion-types e and f contain both A- and C-rings.¶

3-Phenyl-4,1-benzoxathiepin-5-ones 6–8.—In spite of their structural similarity to the 1,5-benzoxathiepin-2-ones 1–5, the 4,1-benzoxathiepin-5-ones 6–8 exhibit markedly different fragmentation patterns. In the parent system 6, decarbonylation of the molecular ion 6i accounts for the low-intensity peak at m/z 228(1%), which is attributed to



Fig. 1 Proposed intra-annular rearrangements in 4-phenyl-1,5-benzoxathiepin-2-one **1** resulting in the extrusion of: (a) ketene and (b) 1,3-benzoxathiolan-2-one.

J. Chem. Research (S), 1999, 584–585†

^{*} To receive any correspondence.

[†]This is a **Short Paper** as defined in the Instructions for Authors, Section 5.0 [see *J. Chem. Research* (*S*), 1999, Issue 1]; there is therefore no corresponding material in *J. Chem. Research* (*M*). [‡]Part 19: ref. 1.

[§]Present address: Department of Chemistry, University of the North, Private Bag X1106, Sovenga, 0727, South Africa.

 $[\]P$ See Scheme 1 for ring designations. In previous studies,⁶ the designations have followed the convention used for the flavanoid precursors.

Table 1 Selected peaks (m/z; followed, in parentheses, by % relative abundance) from El mass spectra of benzoxathiepines 1–12, classified according to ion types a-u

R	lon type						
5-benzoxathiep	<i>in-2-ones</i> (Schem a/b	ne 1) c	d	e	f	q	h
		-	-	-		0	
Н	256(10)	131(100)	103(46)	214(2)	213(10)	137(9)	104(20)
Br ^a	334(6)	209(100)	181(9)	292(1)	291 (3)	137(7)	182(10)
Cl ^b	290(8)	165(100)	137(23)	248(1)	247(4)	137(23)	138(12)
F	274(12)	149(100)	121(39)	232(2)	231(11)	137(8)	122(25)
OMe	286(11)	161(100)	133(19)	244(1)	243(5)	137(4)	134(24)
1 <i>-benzoxathiep</i>	<i>in-</i> 5- <i>ones</i> (Schem	ie 2) j	k	I	m	n	
н	256(21)	228(1)	165(93)	137(69)	136(100)	108(36)	
Br ^a	334(5)	306(0.5) ^c	165(100)	137(64)	136(78)	108(23)	
Cl ^b	290(9)	262(0.6) ^c	165(100)	137(78)	136(76)	108(22)	
1-benzoxathiep	ines (Scheme 3)						
	0	р	q	r	S	t	u
н	242(19)	104(10)	103(5)	151(100)	123(60)	122(96)	121(93)
Br ^a	320(5)	$182(2)^{c}$	$181(0.7)^{c}$	151(100)	123(51)	122(82)	121(76)
Cl ^b	276(8)	138(3)	137(3)	151(100)	123(50)	122(73)	121(67)
F	260(14)	122(100) ^d	121 (93)	151 (96)	123(69)	122(100) ^d	121 (93)
	R 5- <i>benzoxathiep</i> H Br ^a Cl ^b 1- <i>benzoxathiep</i> H Br ^a Cl ^b 1- <i>benzoxathiep</i> H Br ^a Cl ^b	R Ion type 5-benzoxathiepin-2-ones (Schem a/b a/b H 256(10) Br ^a 334(6) Cl ^b 290(8) F 274(12) OMe 286(11) 1-benzoxathiepin-5-ones (Schem H 256(21) Br ^a 334(5) Cl ^b 290(9) 1-benzoxathiepines (Scheme 3) H 256(21) Br ^a 334(5) Cl ^b 290(9) 1-benzoxathiepines (Scheme 3) H 242(19) Br ^a 320(5) Cl ^b 276(8) F 260(14)	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	R Ion type 5-benzoxathiepin-2-ones (Scheme 1) a/b c d H 256(10) 131(100) 103(46) Br ^a 334(6) 209(100) 181(9) Cl ^b 290(8) 165(100) 137(23) F 274(12) 149(100) 121(39) OMe 286(11) 161(100) 133(19) 1-benzoxathiepin-5-ones (Scheme 2) k H 256(21) 228(1) 165(93) Br ^a 334(5) 306(0.5) ^c 165(100) Cl ^b 290(9) 262(0.6) ^c 165(100) 1-benzoxathiepines (Scheme 3) H 256(21) 228(1) 165(100) Cl ^b 290(9) 262(0.6) ^c 165(100) 1-benzoxathiepines (Scheme 3) H 242(19) 104(10) 103(5) Br ^a 320(5) 182(2) ^c 181(0.7) ^c Cl ^b 276(8) <td< td=""><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td><td>R Ion type 5-benzoxathiepin-2-ones (Scheme 1) a/b c d e f H 256(10) 131(100) 103(46) 214(2) 213(10) Br^a 334(6) 209(100) 181(9) 292(1) 291(3) Cl^b 290(8) 165(100) 137(23) 248(1) 247(4) F 274(12) 149(100) 121(39) 232(2) 231(11) OMe 286(11) 161(100) 133(19) 244(1) 243(5) 1-benzoxathiepin-5-ones (Scheme 2) i j k I m H 256(21) 228(1) 165(93) 137(69) 136(100) Br^a 334(5) 306(0.5)^c 165(100) 137(64) 136(76) 1-benzoxathiepines (Scheme 3) - - s - H 242(19) 104(10) 103(5) 151(100) 123(60) Br^a 320(5) 182(2)^c 181(0.7)^c 151(100) 123(51) <!--</td--><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td></td></td<>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	R Ion type 5-benzoxathiepin-2-ones (Scheme 1) a/b c d e f H 256(10) 131(100) 103(46) 214(2) 213(10) Br ^a 334(6) 209(100) 181(9) 292(1) 291(3) Cl ^b 290(8) 165(100) 137(23) 248(1) 247(4) F 274(12) 149(100) 121(39) 232(2) 231(11) OMe 286(11) 161(100) 133(19) 244(1) 243(5) 1-benzoxathiepin-5-ones (Scheme 2) i j k I m H 256(21) 228(1) 165(93) 137(69) 136(100) Br ^a 334(5) 306(0.5) ^c 165(100) 137(64) 136(76) 1-benzoxathiepines (Scheme 3) - - s - H 242(19) 104(10) 103(5) 151(100) 123(60) Br ^a 320(5) 182(2) ^c 181(0.7) ^c 151(100) 123(51) </td <td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td>	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $

 a79 Br data cited for ions containing Br. b 35 Cl data cited for ions containing Cl. c Low-intensity peaks detected (for both 79 Br and 35 Cl species) in a separate experiment on a Finnigan Mat GCQ mass spectrometer. d Peaks for ions **12p**(m/z 122.0532 \equiv C₈H₇F; 30%) and **12t**(m/z 122.0190 \equiv C₇H₆S; 70%) overlap at m/z 122; ratios determined in a separate high-resolution analysis. The % relative abundance figures, however, remain based on the low-resolution data.

the benzoxathiane radical cation 6j (Scheme 2); the corresponding peaks in the spectra of the halogenated analogues 7 and 8 are even less intense. On the other hand, loss of C_7H_7 and contraction of the heterocycle leads to a cascade of A-ring fragments having the same mass as the corresponding parent systems, viz., ions k (m/z 165), l (m/z 137), **m** $(m/z \ 136)$ and **n** $(m/z \ 108)$, the fragmentations $\mathbf{i} \rightarrow \mathbf{k} \rightarrow \mathbf{l}$ and $m \to n$ being supported by the metastable peaks indicated in Scheme 2. In the absence of metastable peak data, the origin of fragments of type **m** remains uncertain; possibilities include: (i) $\mathbf{l} \rightarrow \mathbf{m}$ via loss of \mathbf{H} ; (ii) $\mathbf{k} \rightarrow \mathbf{m}$ *via* loss of H[·] and CO; or (iii) $\mathbf{i} \rightarrow \mathbf{m}$ via loss of a styrene oxide equivalent. The common fragment responsible for the base peak in the spectra of the halogenated derivatives 7 and 8 is the resonance-stabilised 3,1-benzoxathian-4-one cation \mathbf{k} , whereas the parent system 6 affords the thione species 6m as the base peak.



Scheme 3 Mass-spectral fragmentation pathways for 3-phenyl-4,1-benzoxathiepine 9 (R = H). Other details as for Scheme 1.

3-Phenyl-4,1-benzoxathiepines 9–12.—Fragmentation of the molecular ion in these systems leads to peaks attributed to the corresponding C-ring fragments **p**, subsequent loss of H· affording the ions of type **q** (Scheme 3). Elimination of the C-ring (as RC_7H_6) and concomitant contraction of the B-ring accounts for the formation of the resonance-stabilised cation **r** (m/z 151), which is common to each of the compounds examined and generally responsible for the base peak. This and the subsequent fragmentations $[\mathbf{r} \rightarrow \mathbf{s} \ (m/z \ 123)$ and $\mathbf{r} \rightarrow \mathbf{t} \ (m/z \ 122)]$ are all supported by metastable peaks in the mass spectrum of the parent system 9. While fragmentation of cation \mathbf{r} may afford, *via* loss of HCHO, the even-electron species $\mathbf{u} \ (m/z \ 121)$, the alternative pathway $\mathbf{t} \rightarrow \mathbf{u}$ is also possible. Not surprisingly, the fragments \mathbf{r} and \mathbf{t} correspond to the equally abundant ions \mathbf{k} and \mathbf{m} , observed in the mass spectra of the 5-oxo analogues **6–8**, respectively (Scheme 2).

Experimental

The synthesis and characterisation of the benzoxathiepine derivatives 1-12 have been reported previously.⁴ Low-resolution mass spectra were obtained on Hewlett-Packard 5988A and Finnigan Mat GCQ mass spectrometers. High-resolution data were collected on a Kratos double-focussing magnetic sector instrument (Cape Technikon Mass Spectrometry Unit) using the following protocol: ionisation by electron impact; sample introduction by direct insertion probe; and accurate mass determination by peak matching. Meta-stable peak data were acquired on a graphic recorder using a Kratos high-resolution mass spectrometer.

We thank the Deutscher Akademischer Austauschdienst (DAAD) for a bursary (A.C.G.), Rhodes University and the Foundation for Research Development for generous financial support, and Mr A. Sonemann (Rhodes University) for collecting low-resolution MS data and Dr P. Boshoff (Cape Technikon) for high-resolution data.

Received, 29th March 1999; Accepted, 15th June 1999 Paper E/9/024991

References

- 1 Part 19. J. M. Mphahlele and P. T. Kaye, *Magn. Reson. Chem., submitted.*
- 2 D. M. Floyd, R. V. Moqui, K. S. Atuval, S. Z. Ahmed, S. H. Spergel, J. Z. Gougoutas and M. F. Malley, J. Org. Chem., 1990, 55, 5572.
- 3 L. Bonsignore, G. Loy, D. Secci, A. DeLogu and G. Palmieri, *Farmaco*, 1990, **45**, 1245.
- 4 A. C. Gelebe and P. T. Kaye, Synth. Commun., 1996, 26, 4459.
- 5 A. C. Gelebe and P. T. Kaye, S. Afr. J. Chem., 1992, 45, 109.
- 6 See, for example, P. T. Kaye and J. M. Mphahlele, J. Chem. Res., 1994, (S) 62; (M) 0367.